There are no HER3 directed therapies approved for the treatment of NSCLC or any cancer. The frequency of HER3 overexpression in EGFR-mutated NSCLC has been reported to be The post Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC appeared first on Pharmaceutical Business review.

The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a The post ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato appeared first on Pharmaceutical Business review.

Drugmakers successfully completed a majority of postmarketing requirements and commitments in fiscal 2019, the FDA said it its latest annual report.

BLENREP has been approved as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have secured at least four prior therapies including an anti-CD38 The post GSK secures FDA nod for BLENREP to treat relapsed or refractory multiple myeloma appeared first on Pharmaceutical Business review.

As healthcare marketers strive to keep pace with data technologies for better targeting and conversion, budgeting for 2019 becomes a formidable challenge. Questions about competitive advantages and cost-effectiveness drive conversations. Yet, the focus of forward-thinkers is shifting to better data for targeting faster and sooner in the engagement lifecycle. “We are seeing a dramatic increase in ...

PharmaLeaders is pleased to provide our subscribers with a special offer from our webinar partner and presenter, Collaborative Marketing Solutions (CMS). Get your own Marketing Tech Workshop for Life Sciences:  Full Day or Half Day Sessions Facilitated Exercises & Group Breakout Sessions Customer Segmentation Project Prioritization Project Implementation Roadmap Follow-on Kick-off Call